4D Molecular Therapeutics

About 4D Molecular Therapeutics

4D Molecular Therapeutics (4DMT) is a company focused on innovating genetic medicines to unlock their full potential for large market diseases. They harness directed evolution to create customized and enhanced vectors for transformative therapies aimed at improving patient lives or potentially curing diseases. Their mission emphasizes patient-focused development in partnership with organizations and families to address unmet needs in ophthalmology, pulmonology, and cardiology.

Products & Services

4D-150:A gene therapy for eye diseases such as Diabetic Macular Edema (DME) and Wet Age-Related Macular Degeneration (AMD), showing significant reduction in treatment burden and moving to Phase 3 trials.

4D-710:A gene therapy candidate for treating cystic fibrosis, demonstrating early efficacy and quality of life improvements in clinical trials.

Genetic Medicine Platform:An innovative vector platform and product design engine for developing genetic medicines with proprietary customized vectors optimized for specific diseases in ophthalmology, pulmonology, and cardiology.

Specialties

Gene Therapy Directed Evolution Customized Vectors Ophthalmology Pulmonology Cardiology

Funding History

No funding data available

This company may be bootstrapped or privately funded

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Kirn

Co-Founder & CEO, 4DMT

LinkedIn (Pro only)

F

Fred Kamal

President, Chief Operating Officer

T

Theresa Janke

Chief of Staff, Co-Founder

J

Julie Clark

Chief Medical Officer

D

Dhaval Desai

Chief Development Officer

C

Chris Simms

Chief Commercial Officer

View 64 more team members with Pro

Unlock Full Team Directory

Recent News